Accelerate Your Path to Clinic: Recover 2–3 Months with Integrated DS+DP Solutions
Stop letting fragmented development slow you down.
Traditional sequential development often locks in Drug Substance (DS) decisions before Drug Product (DP) risks are even understood, leading to late-stage formulation failures and costly rework.
At Aragen Life Sciences, we’ve pioneered the “Follow the Molecule” approach—a synchronized, parallel workflow that eliminates silos and puts your molecule on the fast track.
Why Choose the Aragen Integrated Advantage?
Recover 2–3 Months: Shift from sequential to parallel development and significantly compress your clinical timeline.
Reduce CMC Risk: Identify critical issues like solid-state instability, particle size disparities, and excipient incompatibility early—before they become bottlenecks.
12-Month Path to Dossier: A unified 12-month journey from developability assessment to regulatory dossier preparation.
All Under One Roof: Seamlessly transition from discovery to commercialization with end-to-end capabilities that eliminate tech-transfer delays.
The Power of Parallel Execution
Traditional (Sequential)
Aragen Integrated (Parallel)
Longer, fragmented timelines
Shorter, overlapping workflows
High risk of late-stage surprises
Early risk mitigation & predictability
Siloed decision-making
Strong cross-functional collaboration
Delayed patient access
Accelerated delivery of life-changing medicines
Transform your CMC liabilities into strategic competitive advantages. Our experts use Quality by Design (QbD) principles and advanced particle engineering to ensure your molecule is not just fast, but robust and regulatory-ready.
Ready to accelerate your timeline? Fill out the form below to consult with our integrated solutions team and learn how we can recover months on your next program.
